{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:09Z","timestamp":1794047469226,"version":"4.8.0"},"reference-count":24,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The patterns of low-risk myelodysplastic syndrome (MDS) progression and the clinical and molecular features of those patterns have not been well described. We divided our low-risk (LR) MDS patients (N=1,914) into 4 cohorts: 1) patients who remained LR-MDS (LR-LR; N=1,300; 68%), 2) patients who progressed from LR to high-risk (HR) MDS (LR-HR) without transformation into acute myeloid leukemia (AML) (N=317; 16.5%), 3) patients who progressed from LR to HR MDS and then AML (LR-HR-AML; N=124; 6.5%), and 4) patients who progressed from LR MDS directly to AML (LR-AML; N=173; 9%). Risk factors for progression included: male gender, low absolute neutrophil count (ANC), low platelet count, high bone marrow (BM) blasts, ferritin &gt;1000 mcg\/L, albumin &lt;3.5 g\/dL, multi-lineage dysplasia (MLD), and lack of ring sideroblasts. Among patients with marked BM fibrosis (N=49), 18% progressed directly to AML. Somatic mutations (SM) associated with an increased risk of direct or indirect AML progression included SRSF2 and NRAS. SM in IDH1, IDH2 and NPM1 were more common in patients with direct AML transformation. SM associated with progression to higher risk disease only, without AML transformation, were ASXL1, TP53, RUNX1, and CBL. SF3B1 mutation was associated with less progression. About 171 patients (13.1% of all LR-LR patients) died within two years of diagnosis of LR-MDS without disease progression. Among the 61 cases with documented cause of death, 18 patients (29.5%) died from cytopenia and MDS-related complications. Identifying patterns of disease progression of LR MDS patients and their predictive factors will be crucial to be able to tailor therapy accordingly.<\/jats:p>","DOI":"10.3324\/haematol.2023.283661","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T05:38:36Z","timestamp":1706765916000},"page":"2157-2164","source":"Crossref","is-referenced-by-count":11,"title":["Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia"],"prefix":"10.3324","volume":"109","author":[{"given":"Akriti G.","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somedeb","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"Al Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kaldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tinsley-Vance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"63273","doi-asserted-by":"crossref","unstructured":"Greenberg P, Cox C, LeBeau MM. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-2088.","DOI":"10.1182\/blood.V89.6.2079"},{"key":"63274","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Tuechler H, Schanz J. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-2465.","DOI":"10.1182\/blood-2012-03-420489"},{"key":"63275","doi-asserted-by":"crossref","unstructured":"Kantarjian H, O\u2019Brien S, Ravandi F. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113(6):1351-1361.","DOI":"10.1002\/cncr.23697"},{"key":"63276","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Shan J, Faderl S. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008; 22(3):538-543.","DOI":"10.1038\/sj.leu.2405070"},{"key":"63277","doi-asserted-by":"crossref","unstructured":"Malcovati L, Germing U, Kuendgen A. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25(23):3503-3510.","DOI":"10.1200\/JCO.2006.08.5696"},{"key":"63278","doi-asserted-by":"crossref","unstructured":"Komrokji RS, Zhang L, Bennett JM. Myelodysplastic syndromes classification and risk stratification. Hematol Oncol Clin North Am. 2010; 24(2):443-457.","DOI":"10.1016\/j.hoc.2010.02.004"},{"key":"63279","doi-asserted-by":"crossref","unstructured":"Volpe VO, Garcia-Manero G, Komrokji RS. Myelodysplastic syndromes: a new decade. Clin Lymphoma Myeloma Leuk. 2022; 22(1):1-16.","DOI":"10.1016\/j.clml.2021.07.031"},{"key":"63280","doi-asserted-by":"crossref","unstructured":"de Swart L, Smith A, Johnston TW. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015; 170(3):372-383.","DOI":"10.1111\/bjh.13450"},{"key":"63281","doi-asserted-by":"crossref","unstructured":"Komrokji R, Ramadan H, Al Ali N. Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2015; 15:Suppl-63.","DOI":"10.1016\/j.clml.2015.03.011"},{"key":"63282","doi-asserted-by":"crossref","unstructured":"Kawabata H, Usuki K, Shindo-Ueda M. Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. Int J Hematol. 2019; 110(5):533-542.","DOI":"10.1007\/s12185-019-02710-1"},{"key":"63283","doi-asserted-by":"crossref","unstructured":"Angelucci E, Greenberg P, Izquierdo M, Garcia-Manero G. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes. Ann Intern Med. 2020; 173(7):595-596.","DOI":"10.7326\/L20-1056"},{"key":"63284","doi-asserted-by":"crossref","unstructured":"Leitch HA, Parmar A, Wells RA. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017; 179(1):83-97.","DOI":"10.1111\/bjh.14825"},{"key":"63285","doi-asserted-by":"crossref","unstructured":"Bejar R, Stevenson KE, Caughey BA. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012; 30(27):3376-3382.","DOI":"10.1200\/JCO.2011.40.7379"},{"key":"63286","unstructured":"Bernard E, Tuechler H, Greenberg Peter L. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evidence. 2022; 1(7):EVIDoa2200008."},{"key":"63287","doi-asserted-by":"crossref","unstructured":"Aguirre LE, Al Ali N, Ball S. Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes. Blood. 2022; 140(Suppl 1):1125-1127.","DOI":"10.1182\/blood-2022-170878"},{"key":"63288","doi-asserted-by":"crossref","unstructured":"Komrokji RS, George TI, Erba HP. Treatment patterns and outcomes of patients with lower-risk myelodysplastic syndromes in the connect \u00ae myeloid disease registry. Blood. 2021; 138(Suppl 1):3686.","DOI":"10.1182\/blood-2021-145853"},{"key":"63289","doi-asserted-by":"crossref","unstructured":"M\u0105dry K, Lis K, Fenaux P. Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): a report from the European MDS registry. Br J Haematol. 2023; 200(4):451-461.","DOI":"10.1111\/bjh.18542"},{"key":"63290","doi-asserted-by":"crossref","unstructured":"Cutler CS, Lee SJ, Greenberg P. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104(2):579-585.","DOI":"10.1182\/blood-2004-01-0338"},{"key":"63291","doi-asserted-by":"crossref","unstructured":"Jain AG, Elmariah H. BMT for Myelodysplastic syndrome: when and where and how. Front Oncol. 2021; 11:771614.","DOI":"10.3389\/fonc.2021.771614"},{"key":"63292","doi-asserted-by":"crossref","unstructured":"de Witte T, Bowen D, Robin M. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017; 129(13):1753-1762.","DOI":"10.1182\/blood-2016-06-724500"},{"key":"63293","doi-asserted-by":"crossref","unstructured":"Della Porta MG, Malcovati L, Strupp C. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011; 96(3):441-449.","DOI":"10.3324\/haematol.2010.033506"},{"key":"63294","doi-asserted-by":"crossref","unstructured":"Naqvi K, Garcia-Manero G, Sardesai S. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011; 29(16):2240-2246.","DOI":"10.1200\/JCO.2010.31.3353"},{"key":"63295","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Natarajan P, Silver AJ. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017; 377(2):111-121.","DOI":"10.1056\/NEJMoa1701719"},{"key":"63296","doi-asserted-by":"crossref","unstructured":"Fuster JJ, MacLauchlan S, Zuriaga MA. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017; 355(6327):842-847.","DOI":"10.1126\/science.aag1381"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283661\/76589","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283661\/77181","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11425\/76589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:39Z","timestamp":1794045939000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283661","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}